Home > News > BioSante Pharmaceuticals Reports Product Development Highlights
May 16th, 2005
BioSante Pharmaceuticals Reports Product Development Highlights
Abstract:
BioSante Pharmaceuticals (AMEX:BPA) today reported on certain product development highlights and announced financial results for the first quarter ended March 31, 2005.
"The completion of our pivotal Phase III clinical trial of Bio-E-Gel(TM) and two key announcements highlighting the use of our CaP nanotechnology represent important progress for BioSante," said Stephen M. Simes, BioSante's president and chief executive officer.
Source:
genengnews.com
Bookmark:
| Related News Press |
Nanomedicine
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Unveiling the power of hot carriers in plasmonic nanostructures August 16th, 2024
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
Financial Reports
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
Arrowhead Pharmaceuticals to Webcast Fiscal 2021 Second Quarter Results April 16th, 2021
 |
||
 |
||
| The latest news from around the world, FREE | ||
 |
||
|
|
||
| Premium Products | ||
 |
||
|
Only the news you want to read!
Learn More |
||
 |
||
|
Full-service, expert consulting
Learn More |
||
|
|
||